Analyst Upgrades: Facebook Inc, FireEye Inc, and Juno Therapeutics Inc

Analysts upwardly revised their ratings on Facebook Inc (FB), FireEye Inc (FEYE), and Juno Therapeutics Inc (JUNO)

by Alex Eppstein

Published on Aug 18, 2015 at 8:55 AM
Updated on Jun 24, 2020 at 10:16 AM

Analysts are weighing in today on social network Facebook Inc (NASDAQ:FB), cybersecurity firm FireEye Inc (NASDAQ:FEYE), and drugmaker Juno Therapeutics Inc (NASDAQ:JUNO). Here's a quick roundup of today's bullish brokerage notes on FB, FEYE, and JUNO.

  • FB saw its price target raised to $120 from $105 at MKM Partners. The bullish brokerage attention is par for the course, as 27 of 29 analysts rate Facebook Inc a "buy" or better -- with not a single "sell" recommendation in sight -- while its consensus 12-month price target of $111.27 sits in uncharted territory. The optimism contrasts sharply with what we're seeing in the options pits, where the stock's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.58 ranks in the 90th percentile of its annual range. On the charts, FB has advanced over 20% year-to-date to trade at $93.93, and less than one month ago touched a record high of $99.24. A capitulation among the bearish holdouts in options land could provide another catalyst higher.

  • Imperial Capital boosted its opinion on FEYE to "outperform" from "in-line," and raised its price target to $55 from $45.50. As such, the shares are pointed 1.2% higher ahead of the bell, and could add to their more than 38% year-to-date gain, as of Monday's close at $43.65. As with FB, FireEye Inc faces skepticism among option traders. The stock's 10-day ISE/CBOE/PHLX put/call volume ratio rests at a 12-month high of 0.87. Should these bears begin to hit the exits, FEYE could catch a tailwind.

  • FBR Capital Markets initiated coverage on JUNO with an "outperform" rating, despite the stock being down 20.4% year-to-date. Thanks to the bullish attention, though, the security is poised to pop nearly 2% at the open. On the sentiment front, positivity is nothing new for Juno Therapeutics Inc -- among the brokerage bunch, at least. Eighty percent of covering analysts consider the shares worthy of a "strong buy" rating, with not a single "sell" assessment to be found. Plus, JUNO's consensus 12-month price target of $63.80 stands at a 53.5% premium to last night's settlement at $41.56.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!


A Schaeffer's 39th Anniversary Exclusive!

8 Top Stock Picks for 2020

Access your FREE insider report before it's too late!


  
 
 

Partnercenter